{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:00:59Z","timestamp":1790766059497,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013738","name":"Pacira Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijid.2022.06.061","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T16:05:00Z","timestamp":1656950700000},"page":"953-956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series"],"prefix":"10.1016","volume":"122","author":[{"given":"Marylene","family":"Duah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8593-8131","authenticated-orcid":false,"given":"Melissa","family":"Beshay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.06.061_bib0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1513\/AnnalsATS.201304-085OC","article-title":"Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease","volume":"11","author":"Adjemian","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijid.2022.06.061_bib0002","doi-asserted-by":"crossref","first-page":"e01947","DOI":"10.1128\/AAC.01947-20","article-title":"In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.06.061_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00250-2019","article-title":"Non-tuberculous mycobacterial pulmonary disease","volume":"54","author":"Cowman","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2022.06.061_bib0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.06.061_bib0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2022.06.061_bib0006","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/cid\/ciz1014","article-title":"Omadacycline in the treatment of Mycobacterium abscessus infection","volume":"71","author":"Madariaga","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.06.061_bib0007","first-page":"e5112","article-title":"Utilizing the promise of omadacycline in a resistant, non-tubercular mycobacterial pulmonary infection","volume":"11","author":"Minhas","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.ijid.2022.06.061_bib0008","doi-asserted-by":"crossref","first-page":"ofab002","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2022.06.061_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.06.061_bib0010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O'Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.06.061_bib0011","doi-asserted-by":"crossref","first-page":"ofaa415","DOI":"10.1093\/ofid\/ofaa415","article-title":"Omadacycline for the treatment of Mycobacterium abscessus disease: a case series","volume":"7","author":"Pearson","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2022.06.061_bib0012","first-page":"96","article-title":"Drug resistance in nontuberculous mycobacteria: mechanisms and models","volume":"10","author":"Saxena","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.ijid.2022.06.061_bib0013","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0038-1651494","article-title":"Treatment of Mycobacterium abscessus complex","volume":"39","author":"Strnad","year":"2018","journal-title":"Semin Respir Crit Care Med"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T10:46:40Z","timestamp":1715424400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222003952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":13,"alternative-id":["S1201971222003952"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.06.061","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.06.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}